ArticleMedicine2025
Evaluation of factors influencing xanthelasma palpebrarum in Chinese patients: A case-control study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xanthelasma palpebrarum (XP) is a yellow plaque lesion near the eyelid, which was previously found to be associated with dyslipidemia, metabolic syndrome, and cardiovascular disease. This study aimed to explore the clinical characteristics and potential mechanisms underlying its development by analyzing body mass index (BMI), lipid levels, blood glucose, and blood type in affected individuals. A case-control study was conducted involving 44 patients with XP between 2019 and 2023 and 44 age- and sex-matched healthy controls. Data collection included medical history, BMI, total cholesterol (TC), triglycerides (TG), blood glucose, and blood type. Patients were predominantly female (68.2%) and aged 45-50 years. Compared with healthy controls, patients exhibited significantly higher mean levels of TC and TG (P = .01 and P = .04, respectively). Elevated TC and TG levels were more common in the XP group (TC: 50.0% vs 15.91%; TG: 25.0% vs 6.82%). Hyperglycemia was also more frequent (15.91% vs 0%, P < .05). However, there were no significant differences in mean BMI, blood glucose levels, or overweight prevalence. Blood type distributions were similar between the 2 groups, and no statistically significant differences were found. Multivariate logistic regression analysis revealed that TC, TG, BMI, and blood glucose were not found as independent risk factors for XP. The findings suggest that while dyslipidemia is associated with XP, its development is likely due to the combined influence of lipid abnormalities and genetic predisposition rather than any single clinical factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.